---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019085"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T01:58:38.103978+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Path Q3 net loss $3.2M; positive prexigebersen AML Phase 2 data

## Summary
- Net loss of $3.2M ($0.32/sh) vs $3.5M ($0.49/sh) in Q3 2022, improvement from lower expenses and warrant income.
- Cash $2.4M as of Sep 30, 2023, down from $10.4M at Dec 31, 2022; net cash used in ops $9.7M in nine months.
- Positive Phase 2 interim data for prexigebersen in AML; results exceed outcomes of decitabine/venetoclax alone.
- R&D expense $2.3M (down from $2.4M), G&A $1.0M (down from $1.2M) year-over-year.
- KOL event in October with MD Anderson and Georgia Cancer Center experts discussing prexigebersen potential.

## SEC filing metadata
- accession: 0001558370-23-019085
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837023019085/0001558370-23-019085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837023019085/bpth-20231115x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019085
- JSON: https://secwatch.observer/filing/0001558370-23-019085.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019085.txt

## Key facts
- Earnings Releases
  BIO-PATH HOLDINGS, INC. reported third quarter ended September 30, 2023 results: net income net loss of $3.2 million, or $0.32 per share, EPS $0.32 per share.
  - Period: third quarter ended September 30, 2023
  - Net income: net loss of $3.2 million, or $0.32 per share
  - EPS: $0.32 per share
  - Result: reported results
  source text: The Company reported a net loss of $3.2 million, or $0.32 per share, for the three months ended September 30, 2023, compared to a net loss of $3.5 million, or $0.49 per share, for the three months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133818/000155837023019085/0001558370-23-019085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.